NBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
NovaBridge Biosciences
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026
$1.30+0.04 (+3.17%)
Close on Oct 19, 2026
NovaBridge Biosciences revenue by segment
By business segment
By product or service
| Revenue | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Licensing and collaboration revenue | CN¥16.81M | -CN¥249.67M | CN¥40.12M | CN¥1.54B | CN¥30.00M | 60.8% | -106.7% |
| Supply of investigational products | CN¥10.83M | CN¥28.10M | CN¥47.91M | CN¥0 | CN¥0 | 39.2% | -61.5% |
| Grant | – | CN¥18.90M | – | CN¥10.00M | – | – | – |
| Pipeline [Member] | – | – | CN¥4.50M | – | – | – | – |
| Paycheck protection program loan | – | – | CN¥2.90M | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of NovaBridge Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.